Materials and methods

83
Chemicals
84
Colistin sulfate and sodium colistin methanesulfonate were from Sigma-Aldrich 85 (Missouri, USA) and Link Pharmaceuticals Ltd (Auckland, New Zealand), respectively. All
86
Male Sprague-Dawley rats (300-320 g) were acclimated for a minimum of seven days in the 93 faculty animal house within a temperature range of 18-24°C, 40-70% relative humidity and 94 12 h light/dark cycles. Food and water were available ad libitum during the acclimation 95 period and throughout the study. The day prior to the pharmacokinetic study, the right carotid 96 artery of each rat was cannulated for collection of blood samples; the jugular vein was 97 cannulated for IV dosing. Following surgery, rats were individually housed in metabolic 98 cages and allowed 24 h for recovery.
99
Drug formulations and administration
100
Immediately prior to IV and pulmonary administration, CMS (sodium) and colistin
101
(sulfate) dosing solutions were freshly prepared in sterile 0.9% sodium chloride (Baxter
102
Healthcare Pty Ltd, New South Wales, Australia). For the IV studies, CMS or colistin 
106
For IT instillation, rats were lightly anesthetized with gaseous isoflurane (Delvert Pty Ltd, 107 New South Wales, Australia) and rested in a supine position against a restraining board 108 angled at approximately 60-70° from the horizontal. The tongue of the rat was gently pulled 109 outwards using forceps, and the blade of a small animal laryngoscope (PennCentury Inc, the dosing solution from the syringe and cannula. Following IT instillation, rats were returned 116 to metabolism cages where they rapidly recovered from the isoflurane anesthesia.
117
Pharmacokinetic studies 118 Animals were administered IV CMS at doses of 14 mg/kg, 28 mg/kg or 56 mg/kg 119 (n=3 per dose). Blood samples (320 μL) were collected via the carotid artery prior to dosing 120 and at 0.08, 0.25, 0.5, 1, 2, 3 and 4 h post-dosing. In an independent study, rats were 121 administered IV colistin at doses of 0.21 mg/kg, 0.41 mg/kg or 0.62 mg/kg (n=3 per dose); 122 blood samples (200 μL) were collected prior to dosing and at 0. 02, 0.05, 0.08, 0.17, 0.33, 0.5, 123 1, 1.5, 2, 2.5, 3, 3.5 and 4 h post-dose. In the dose-ranging CMS study above, blood samples 124 were immediately placed on ice prior to centrifugation (6,700 × g, 4°C, 10 min), to minimize 125 any potential in vitro conversion of CMS to colistin. Additionally, any potential in vitro 126 conversion was minimized by storage of plasma samples at -80ºC, and subsequent HPLC 127 analysis within 4 months of collection (21).
128
For the pulmonary dosing studies, two cohorts of animals were required to fully 129 characterize systemic and lung exposure. Rats in the first cohort were administered IT CMS 130 at doses of 14 mg/kg or 28 mg/kg (n=3 per dose). Blood samples (320 μL) were collected 131 pre-dose and at 0.08, 0.5, 1, 2, 3, 4, 5, 6 and 8 h post-dose. In the second cohort, rats received 132 a pulmonary dose of 14 mg/kg CMS, to allow for the collection of terminal bronchoalveolar 133 lavage (BAL) fluid and a corresponding blood sample. Samples were collected at 0.08, 0.5, 2, 134 4, 6, 8 and 12 h post-dose (n=3 rats per time point). In a separate study, rats in the first cohort 135 were administered colistin at IT doses of 0.41 mg/kg, 0.62 mg/kg, 0.99 mg/kg or 1.49 mg/kg 136 (n=3 per dose). Blood samples were collected as described above following IV colistin 137 dosing. A second cohort of rats received an IT dose of 0.62 mg/kg colistin; terminal BAL 138 fluid and blood samples were collected as described for IT dosing of CMS. Blood samples were processed as above and the plasma collected to quantify drug and urea concentrations 140 (for the second cohort of rats). Bronchoalveolar lavage and processing of BAL fluid samples 141 were undertaken as detailed below.
142
The lowest dosages in these studies were selected based on the quantification limits of 143 the analytical methods in both plasma and in BAL fluid, whereas the higher dosages for IV 144 CMS were defined on the basis of known tolerability in rats (22) . IT administration of 56 145 mg/kg CMS was not well tolerated and therefore only two CMS IT dosages were evaluated.
146
Colistin dosages were selected to achieve plasma concentrations known to be well tolerated 147 by the animals.
148
Bronchoalveolar lavage
149
Rats were anesthetized with gaseous isoflurane and sacrificed via exsanguination. For 150 BAL, the trachea was exposed and a small incision made to allow the insertion of a PE tube 
204
First-order and mixed-order kinetics were tested to describe the conversion of CMS to 205 colistin, and absorption of both compounds from the lungs into the systemic circulation.
206
These models also explored whether a delay (represented by a series of transit (Tr) 207 compartments) in conversion or absorption was required to adequately fit the data. The between-subject variability (BSV) in parameter estimates was assumed to follow 211 a log-normal distribution, with the magnitude reported as a coefficient of variation (CV).
212
Residual unexplained variability (RUV) in the plasma model was evaluated using a combined since only a single observation was obtained from each rat due to terminal BAL sampling.
217
Data below the LOQ were handled using a likelihood-based (M3) method (27).
218
Visual inspection of diagnostic scatter plots, the objective function value (OBJ,
219
reported as -1 × log likelihood in S-ADAPT) and the biological plausibility of the parameter 220
estimates were used for model selection. Statistical comparison of the models was performed 221 using a χ 2 test; a decrease in the OBJ of 1.92 units (α = 0.05) was considered significant.
222
The final model was evaluated by performing a visual predictive check (VPC). For 223 this, 1000 data sets were simulated from the final parameter estimates using the original data.
224
The median and the 10 th and 90 th percentiles (25 th and 75 th percentiles for the ELF models) of 
230
Histopathology 231 Histopathology examination was undertaken to determine whether cellular damage to 232 the lung epithelium occurred following pulmonary dosing of CMS or colistin. Two control 233 groups (n=3 rats per group), were dosed with 100 μL of blank saline via IT instillation; the treatment groups (n=3 rats per group) received either 14 mg/kg CMS or 0.62 mg/kg colistin 235 (doses corresponding to the studies where BAL fluid was collected) in a 100 μL aliquot.
236
Following dosing, rats were anesthetized and sacrificed via exsanguination at 4 h (for CMS) 237 or 0.75 h (for colistin); sample collection times reflect maximal concentrations in plasma.
238
The trachea was exposed and an incision made to allow for the insertion of an 18G needle. 
271
Population pharmacokinetic model
272
In the full composite model, the disposition of both CMS and colistin in plasma was 273 best described by a three-compartment model. Table 1 an additional pathway incorporating zero-order with sequential delayed first-order absorption,
305
was required to fit the high concentrations observed at 2-3 h in plasma ( Figure 3D ). This that was 8000-fold higher than that in plasma after IV dosing ( Figure 4B ).
314
Histopathology examination
315
Histopathology examination of the trachea and lung lobes following IT administration 316 of either CMS or colistin showed no significant difference between the control and treatment 317 groups (data not shown).
318
Discussion
319
The current study evaluates the pharmacokinetics of CMS and colistin following IV 320 and IT administration of both compounds in rats. arising from NCA after IV administration of CMS (17, 28, 29) and colistin (30) in rats.
334
There is limited knowledge on the mechanism by which colistin is formed from CMS in ELF compared to conversion in plasma after IV administration (3%) ( Figure 4A ). This in ELF and the corresponding delay in its plasma appearance after IT administration of CMS.
365
With limited information available about the conversion mechanism of CMS to colistin, one 366 potential explanation for the slower, but ultimately more extensive conversion observed in 367 the lungs is that while CMS resides within the lung it is not available for renal clearance, 368 which is the major systemic clearance mechanism (11). A further contributing factor to the 369 increased ELF exposure is that CMS will be dissolved within a relatively small volume of infected animals, it can be adapted to the estimation of known PK differences in infected murine models (47-49). Ultimately, these models could be usefully employed to develop 427 inhalational dosing recommendations for CMS in CF patients that simultaneously consider 428 target endpoints in respiratory infection whilst avoiding potential adverse effects.
429
In conclusion, we have for the first time developed a detailed model that describes the 430 pharmacokinetics of CMS and colistin after both IV and IT administration. We demonstrate 
